Socialiya - Entertainment. Knowledge. Community.
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — bo...

BUSINESS NEWS June 09, 2026

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

2 views 0 likes 0 comments
Share:
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

Author: Endpoints News

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya